tbuckley/cabot-search huggingface dataset:
Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
Authors: Simone de Vries, Miriam L. Haaksma, Katarzyna Jóźwiak, Michael Schaapveld, David C. Hodgson, Pieternella J. Lugtenburg, Augustinus D.G. Krol, Eefke J. Petersen, Dick Johan van Spronsen, Sameera Ahmed, Michael Hauptmann, Berthe M.P. Aleman, Flora E. van Leeuwen
Journal: Journal of Clinical Oncology (2022)

Previous efforts to predict absolute risk of treatment-related cardiovascular diseases (CVDs) have mostly focused on childhood cancer survivors. We aimed to develop prediction models for risk of coronary heart disease (CHD) and heart failure (HF) for survivors of adolescent/adult Hodgkin lymphoma (HL).For model development, we used a multicenter cohort including 1,433 5-year HL survivors treated between 1965 and 2000 and age 18-50 years at HL diagnosis, with complete data on administered chemotherapy regimens, radiotherapy volumes and doses, and cardiovascular follow-up. Using cause-specific hazard models, covariate-adjusted cumulative incidences for CHD and HF were estimated in the presence of competing risks of death because of other causes than CHD and HF. Age at HL diagnosis, sex, smoking status, radiotherapy, and anthracycline treatment were included as predictors. External validation for the CHD model was performed using a Canadian cohort of 708 HL survivors treated between 1988 and 2004 and age 18-50 years at HL diagnosis.After a median follow-up of 24 years, 341 survivors had developed CHD and 102 had HF. We were able to predict CHD and HF risk at 20 and 30 years after treatment with moderate to good overall calibration and moderate discrimination (areas under the curve: 0.68-0.74), which was confirmed by external validation for the CHD model (areas under the curve: 0.73-0.74). On the basis of our model including prescribed mediastinal radiation dose, 30-year risks ranged from 4% to 78% for CHD and 3% to 46% for HF, depending on risk factors.We developed and validated prediction models for CHD and HF with good overall calibration and moderate discrimination. These models can be used to identify HL survivors who might benefit from targeted screening for CVD and early treatment for CVD risk factors.
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
Authors: A. Cortellini, A.P.C. Barrichello, J.V. Alessi, B. Ricciuti, V.R. Vaz, T. Newsom-Davis, J.S. Evans, G. Lamberti, F. Pecci, P. Viola, A. D’Alessio, C.A.M. Fulgenzi, M.M. Awad, D.J. Pinato
Journal: Annals of Oncology (2022)
Frequent bleeding symptoms associated with autoimmune acquired factor <scp>XIII</scp>/13 deficiency due to anti‐factor <scp>XIII</scp> A and B subunit antibodies
Authors: Shuji Ozaki, Makiko Mizuguchi, Yasunobu Okamoto, Hikaru Yagi, Kumiko Kagawa, Hironobu Shibata, Keiji Yoda, Masayoshi Souri, Akitada Ichinose
Journal: American Journal of Hematology (2022)

There are no conflict of interest to declare.
The impact of weekday, weekend, and holiday crashes on motorcyclist injury severities: Accounting for temporal influence with unobserved effect and insights from out-of-sample prediction
Authors: Chamroeun Se, Thanapong Champahom, Sajjakaj Jomnonkwao, Nopadon Kronprasert, Vatanavongs Ratanavaraha
Journal: Analytic Methods in Accident Research (2022)
Investigating the effects of sleepiness in truck drivers on their headway: An instrumental variable model with grouped random parameters and heterogeneity in their means
Authors: Amir Pooyan Afghari, Eleonora Papadimitriou, Fran Pilkington-Cheney, Ashleigh Filtness, Tom Brijs, Kris Brijs, Ariane Cuenen, Bart De Vos, Helene Dirix, Veerle Ross, Geert Wets, André Lourenço, Lourenço Rodrigues
Journal: Analytic Methods in Accident Research (2022)

Sleepiness is a common human factor among truck drivers resulting from sleep loss or time of day and causing impairment in vigilance, attention, and driving performance. While driver sleepiness may be associated with increased risk on the road, sleepy drivers may drive more cautiously as a result of risk-compensating behaviour. This endogeneity has been overlooked in the previous driver behaviour studies and may provide new insight into the effects of sleepiness on driving performance. In addition, the Karolinska Sleepiness Scale (KSS) has been widely used to quantify sleepiness. However, the KSS is a subjective self-reported measure and is reliant on honest reporting and understanding of the scale. An alternative way of quantifying sleepiness is using drivers' heart rate and correlating it with their sleepiness. While recent advances in data collection technologies have made it possible to collect heart rate data in real-time and in an unobtrusive way, their application in measuring sleepiness particularly among truck drivers has been unexplored. This study aims to address these gaps and contribute to analytic methods in road safety research by collecting truck drivers' heart rate data in real-time, measuring sleepiness from those data, and using it in an instrumental variable modelling framework to investigate its effect on driving performance. To this end, a driving simulator experiment was conducted in Belgium and heart rate data were collected for 35 truck drivers via sensors installed on the steering wheel of the simulator. Additional demographic data were collected using a questionnaire before the experiment. An instrumental variable model consisting of a discrete binary logit and a continuous generalized linear model with grouped random parameters and heterogeneity in their means was then developed to study the effects of driver sleepiness on headway. Results indicate that age, years of holding driver licence, road type, type of truck transport, and weekly distance travelled are significantly associated with sleepiness among the participants of this study. Sleepy driving is associated with reduced headway for 30.5% of the drivers and increased headway for the other 69.5%, and night-time shift is associated with such varied effects. These findings indicate that there may be group- or context-specific risk patterns which cannot be explicitly addressed by hours of service regulations and therefore, transport operators, driver trainers and fleet managers should identify and handle such context-specific high risk patterns in order to ensure safe operations.
Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique
Authors: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, Mahmoud Abou Zeinab, Aaron Kaviani, Christopher Weight, Samuel Haywood, Mohamed Eltemamy, Andrei Purysko, Jesse K. McKenney, Eric Klein
Journal: European Urology (2022)
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Authors: Yang Liu, Ning Zhang, Cuicui Xie, Yale Jiang, Yunhe Qin, Liyun Zhou, Yi Fan, Lianjie Ren, Chen Yin, Huan Yang, Wei Xie, Qing Zhai, Guanqiao Li, Hongzhuan Chen, Xiaoyuan Chen
Journal: Acta Pharmaceutica Sinica B (2022)

Over the past two decades, China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals, keeping in line with the rapidly growing scientific innovation in drug research and development (R&D). In this study, we outlined the revolution of drug regulation in China since the establishment of the State Drug Administration in 1998. More particularly, we performed a comprehensive analysis of newly approved anticancer drugs in China from the year 2005 to May 2021, as a powerful illustration of how the revolution has changed the drug R&D landscape. Innovative drug development in China has boomed, benefiting in particular from pro-innovation policies as well as expedited program designations by the authority. We found a significant increase in the number of both imported and domestic new anticancer drugs from 2005 to 2021, with the emergence of drugs with novel mechanisms of action, including immune checkpoint inhibitors and cell therapy products. Drug lag has also been dramatically shortened by more than 70% for imported drugs in years 2016-2020 compared to years 2006-2010. Furthermore, we provide an insight into the potential approaches to further optimize the science-based and clinical value-based regulatory and R&D drug ecosystem in China. This review provides evidence of significant impacts of regulations and policies on drug R&D and suggests that the constantly adapting regulatory ecosystem will speed up drug development in China and worldwide.
Multi-Omics Analyses Provide Insight into the Biosynthesis Pathways of Fucoxanthin in <i>Isochrysis Galbana</i>
Authors: Duo Chen, Xue Yuan, Xuehai Zheng, Jingping Fang, Gang Lin, Rongmao Li, Jiannan Chen, Wenjin He, Zhen Huang, Wenfang Fan, Limin Liang, Chentao Lin, Jinmao Zhu, Youqiang Chen, Ting Xue
Journal: Genomics Proteomics & Bioinformatics (2022)

Abstract Isochrysis galbana is considered an ideal bait for functional foods and nutraceuticals of humans because of its high fucoxanthin (Fx) content. However, multi-omics analysis of the regulatory networks for Fx biosynthesis in I. galbana has not been reported. In this study, we report a high-quality genome assembly of I. galbana LG007, which has a genome size of 92.73 Mb, with a contig N50 of 6.99 Mb and 14,900 protein-coding genes. Phylogenetic analysis confirmed the monophyly of Haptophyta, with I. galbana sister to Emiliania huxleyi and Chrysochromulina tobinii. Evolutionary analysis revealed an estimated divergence time between I. galbana and E. huxleyi of ∼ 133 million years ago. Gene family analysis indicated that lipid metabolism-related genes exhibited significant expansion, including IgPLMT, IgOAR1, and IgDEGS1. Metabolome analysis showed that the content of carotenoids in I. galbana cultured under green light for 7 days was higher than that under white light, and β-carotene was the main carotenoid, accounting for 79.09% of the total carotenoids. Comprehensive multi-omics analysis revealed that the content of β-carotene, antheraxanthin, zeaxanthin, and Fx was increased by green light induction, which was significantly correlated with the expression of IgMYB98, IgZDS, IgPDS, IgLHCX2, IgZEP, IgLCYb, and IgNSY. These findings contribute to the understanding of Fx biosynthesis and its regulation, providing a valuable reference for food and pharmaceutical applications.
Fifty Years of Medical Progress, 1873-1922.
Authors: Harry Drinkwater
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Medical Literature
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systematic review and meta-analyses on the effects of afternoon napping on cognition
Authors: Ruth L.F. Leong, June C. Lo, Michael W.L. Chee
Journal: Sleep Medicine Reviews (2022)

Naps are increasingly considered a means to boost cognitive performance. We quantified the cognitive effects of napping in 60 samples from 54 studies. 52 samples evaluated memory. We first evaluated effect sizes for all tests together, before separately assessing their effects on memory, vigilance, speed of processing and executive function. We next examined whether nap effects were moderated by study features of age, nap length, nap start time, habituality and prior sleep restriction. Naps showed significant benefits for the total aggregate of cognitive tests (Cohen's d = 0.379, CI95 = 0.296-0.462). Significant domain specific effects were present for declarative (Cohen's d = 0.376, CI95 = 0.269-0.482) and procedural memory (Cohen's d = 0.494, CI95 = 0.301-0.686), vigilance (Cohen's d = 0.610, CI95 = 0.291-0.929) and speed of processing (Cohen's d = 0.211, CI95 = 0.052-0.369). There were no significant moderation effects of any of the study features. Nap effects were of comparable magnitude across subgroups of each of the 5 moderators (Q values = 0.009 to 8.572, p values > 0.116). Afternoon naps have a small to medium benefit over multiple cognitive tests. These effects transcend age, nap duration and tentatively, habituality and prior nocturnal sleep.
Moderate-Intensity Exercise and Self-rated Quality of Sleep in Older Adults
Authors: Abby C. King
Journal: JAMA (1997)

<h3>Objective.</h3> —To determine the effects of moderate-intensity exercise training on self-rated (subjective) sleep quality among healthy, sedentary older adults reporting moderate sleep complaints. <h3>Design.</h3> —Randomized controlled trial of 16 weeks' duration. <h3>Setting.</h3> —General community. <h3>Participants.</h3> —Volunteer sample of 29 women and 14 men (of 67 eligible subjects) aged 50 to 76 years who were sedentary, free of cardiovascular disease, and reported moderate sleep complaints. No participant was withdrawn for adverse effects. <h3>Intervention.</h3> —Randomized to 16 weeks of community-based, moderate-intensity exercise training or to a wait-listed control condition. Exercise consisted primarily of four 30- to 40-minute endurance training sessions (low-impact aerobics; brisk walking) prescribed per week at 60% to 75% of heart rate reserve based on peak treadmill exercise heart rate. <h3>Main Outcome Measure.</h3> —Pittsburgh Sleep Quality Index (PSQI). <h3>Results.</h3> —Compared with controls (C), subjects in the exercise training condition (E) showed significant improvement in the PSQI global sleep score at 16 weeks (baseline and posttest values in mean [SD] for C=8.93 [3.1] and 8.8 [2.6]; baseline and posttest values for E=8.7 [3.0] and 5.4 [2.8]; mean posttest difference between conditions=3.4; P&lt;.001; 95% confidence interval, 1.9-5.4), as well as in the sleep parameters of rated sleep quality, sleep-onset latency (baseline and posttest values for C=26.1 [20.0] and 23.8 [15.3]; for E=28.4 [20.2] and 14.6 [13.0]; net improvement=11.5 minutes), and sleep duration baseline and posttest scores for C=5.8 [1.1] and 6.0 [1.0]; for E=6.0 [1.1] and 6.8 [1.2]; net improvement=42 minutes) assessed via PSQI and sleep diaries (P=.05). <h3>Conclusions.</h3> —Older adults with moderate sleep complaints can improve selfrated sleep quality by initiating a regular moderate-intensity exercise program.
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
Authors: Khê Hoang-Xuan, Martina Deckert, Andrés J M Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Rudà, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J B Taphoorn, Valérie Touitou, Michael Weller, Jacoline E C Bromberg
Journal: Neuro-Oncology (2022)

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.
Fluorine-thiol displacement probes for acetaminophen's hepatotoxicity
Authors: Benjamin L. Prather, Shuyue Ji, Yue Zhao, Femil Joseph Shajan, Mi Zhao, Zakey Yusuf Buuh, Robert Maloney, Rui Zhang, Carson Cohen, Rongsheng E. Wang
Journal: Acta Pharmaceutica Sinica B (2022)

Chemicals possessing reactive electrophiles can denature innate proteins leading to undesired toxicity, and the overdose-induced liver injury by drugs containing electrophiles has been one of the major causes of non-approval and withdraw by the US Food and Drug Administration (FDA). Elucidating the associated proteins could guide the future development of therapeutics to circumvent these drugs' toxicities, but was largely limited by the current probing tools due to the steric hindrance of chemical tags including the common "click chemistry" labels. Taking the widely used non-steroidal anti-inflammatory drug acetaminophen (APAP) as an example, we hereby designed and synthesized an APAP analogue using fluorine as a steric-free label. Cell toxicity studies indicated our analogue has similar activity to the parent drug. This analogue was applied to the mouse hepatocellular proteome together with the corresponding desthiobiotin-SH probe for subsequent fluorine-thiol displacement reactions (FTDRs). This set of probes has enabled the labeling and pull-down of hepatocellular target proteins of the APAP metabolite as validated by Western blotting. Our preliminary validation results supported the interaction of APAP with the thioredoxin protein, which is an important redox protein for normal liver function. These results demonstrated that our probes confer minimal steric perturbation and mimic the compounds of interest, allowing for global profiling of interacting proteins. The fluorine-thiol displacement probing system could emerge as a powerful tool to enable the investigation of drug-protein interactions in complex biological environments.
Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC)
Authors: Jie Chen, Di Zhao, Lingyuan Zhang, Jing Zhang, Yuanfan Xiao, Qingnan Wu, Yan Wang, Qimin Zhan
Journal: Cellular and Molecular Immunology (2022)

Tumor cell dependence on activated oncogenes is considered a therapeutic target, but protumorigenic microenvironment-mediated cellular addiction to specific oncogenic signaling molecules remains to be further defined. Here, we showed that tumor-associated macrophages (TAMs) produced an abundance of C-C motif chemokine 22 (CCL22), whose expression in the tumor stroma was positively associated with the level of intratumoral phospho-focal adhesion kinase (pFAK Tyr397), tumor metastasis and reduced patient survival. Functionally, CCL22-stimulated hyperactivation of FAK was correlated with increased malignant progression of cancer cells. CCL22-induced addiction to FAK was demonstrated by the persistent suppression of tumor progression upon FAK-specific inhibition. Mechanistically, we identified that diacylglycerol kinase α (DGKα) acted as a signaling adaptor to link the CCL22 receptor C-C motif chemokine receptor 4 (CCR4) and FAK and promoted CCL22-induced activation of the FAK/AKT pathway. CCL22/CCR4 signaling activated the intracellular Ca2+/phospholipase C-γ1 (PLC-γ1) axis to stimulate the phosphorylation of DGKα at a tyrosine residue (Tyr335) and promoted the translocation of DGKα to the plasma membrane to assemble the DGKα/FAK signalosome, which critically contributed to regulating sensitivity to FAK inhibitors in cancer cells. The identification of TAM-driven intratumoral FAK addiction provides opportunities for utilizing the tumor-promoting microenvironment to achieve striking anticancer effects.